Chiesi signs $1.9bn deal to buy KalVista and its HAE drug
Italian pharma group Chiesi has bolstered its rare disease business with an agreement to buy US biopharma KalVista Pharma and Ekterly, the first oral drug for treating exacerbations of the rare disease hereditary angioedema (HAE). Chiesi is offering $27- …